Dose-finding, experimental medicine evaluation of sodium valproate for the prevention of post-cardiac surgery myocardial injury
- 1University of Leicester
Abstract
BackgroundA dose-finding trial evaluated safety and adherence for pre-cardiac surgery administration of sodium valproate. Integrated multi-omics analyses of myocardium were used to characterise mechanisms underlying treatment effects.
MethodsAdults undergoing cardiac surgery were randomised 1:1:1:1 with concealed allocation to no treatment (Controls), sodium valproate 15mg/kg/day for 1-2 weeks, 15mg/kg/day for 4-6 weeks, or 25mg/kg/day for 4-6 weeks pre-surgery. The primary analysis evaluated adherence and toxicity. Myocardial injury was defined by high sensitivity serum troponin at 24 hours post-surgery. Single-nucleus Assay for Transposase-Accessible Chromatin with sequencing (snATACseq) and single nuclei RNA sequencing (snRNAseq) of myocardial biopsies collected at surgery assessed treatment effects on chromatin accessibility and gene expression. Candidate mechanisms were validated in in vitro.
ResultsThe analysis cohort included 42 participants enrolled between January 2020 and August 2024. Sodium valproate 15mg/kg/day for 1-2 weeks had the highest levels of complete treatment adherence (70%), with 20% experiencing moderate/severe drug related adverse effects. Non-compliance was increased with longer and higher dosing.
An as-treated analyses demonstrated reductions in troponin release in participants receiving Valproate[≤]14 days where myocardial biopsies demonstrated activation of hormetic p53 and Akt-GSK-3{beta} ferroptosis protection pathways versus controls. Silencing of these pathways attenuated the protective effect of valproate in vitro. Treatment effects were not attributable to chromatin accessibility.
Treatment >14 days resulted in a heart failure phenotype, suppression of ferroptosis protection pathways, and increased myocardial injury.
ConclusionsValproate 15mg/kg/day for [≤]14 days pre-surgery is well tolerated in adults awaiting cardiac surgery and is associated with upregulation of ferroptosis protection pathways and reductions in myocardial injury.
Related
- The core mechanism of traditional Chinese medicine in improving myocardial fibrosis: restoring the dynamic balance of mitochondrial quality control
- Targeted Medical Interventions for the Prevention and Treatment of Viral Hemorrhagic Fever: A Rapid Systematic Review of Updated Intelligence from the 74th Annual Meeting of the American Society of Tropical Medicine and Hygiene
- Traditional Chinese medicine interventions and mitochondrial communication in myocardial and cerebral ischemia: a critical review
- Effect of animation-based edutainment compared with pamphlet-based education on hand hygiene and HAI prevention among surgical patients: a quasi-experimental study
- Traditional Chinese medicine and RhoA/ROCK signaling in myocardial ischemia/reperfusion injury: a narrative review of preclinical evidence
BibTeX
@misc{roman2026dosefinding,
title = {{Dose-finding, experimental medicine evaluation of sodium valproate for the prevention of post-cardiac surgery myocardial injury}},
author = {M. Roman and N. Beasley and S. S. Ladak and C. U. Solomon and W. Liao and F. Lai and L. Joel-David and H. Aujla and G. Condorelli and M. J. Wozniak and V. Codd and T. R. Webb and C. Brookes and G. J. Murphy},
howpublished = {medRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.30.26361746},
url = {https://www.medrxiv.org/content/10.64898/2026.08.30.26361746v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Dose-finding, experimental medicine evaluation of sodium valproate for the prevention of post-cardiac surgery myocardial injury
AU - M. Roman
AU - N. Beasley
AU - S. S. Ladak
AU - C. U. Solomon
AU - W. Liao
AU - F. Lai
AU - L. Joel-David
AU - H. Aujla
AU - G. Condorelli
AU - M. J. Wozniak
AU - V. Codd
AU - T. R. Webb
AU - C. Brookes
AU - G. J. Murphy
PY - 2026
DA - 2026/08/30
PB - medRxiv
DO - 10.64898/2026.08.30.26361746
UR - https://www.medrxiv.org/content/10.64898/2026.08.30.26361746v1
AB - BackgroundA dose-finding trial evaluated safety and adherence for pre-cardiac surgery administration of sodium valproate. Integrated multi-omics analyses of myocardium were used to characterise mechanisms underlying treatment effects. MethodsAdults undergoing cardiac surgery were randomised 1:1:1:1 with concealed allocation to no treatment (Controls), sodium valproate 15mg/kg/day for 1-2 weeks, 15mg/kg/day for 4-6 weeks, or 25mg/kg/day for 4-6 weeks pre-surgery. The primary analysis evaluated adherence and toxicity. Myocardial injury was defined by high sensitivity serum troponin at 24 hours post-surgery. Single-nucleus Assay for Transposase-Accessible Chromatin with sequencing (snATACseq) and single nuclei RNA sequencing (snRNAseq) of myocardial biopsies collected at surgery assessed treatment effects on chromatin accessibility and gene expression. Candidate mechanisms were validated in in vitro. ResultsThe analysis cohort included 42 participants enrolled between January 2020 and August 2024. Sodium valproate 15mg/kg/day for 1-2 weeks had the highest levels of complete treatment adherence (70%), with 20% experiencing moderate/severe drug related adverse effects. Non-compliance was increased with longer and higher dosing. An as-treated analyses demonstrated reductions in troponin release in participants receiving Valproate[≤]14 days where myocardial biopsies demonstrated activation of hormetic p53 and Akt-GSK-3{beta} ferroptosis protection pathways versus controls. Silencing of these pathways attenuated the protective effect of valproate in vitro. Treatment effects were not attributable to chromatin accessibility. Treatment >14 days resulted in a heart failure phenotype, suppression of ferroptosis protection pathways, and increased myocardial injury. ConclusionsValproate 15mg/kg/day for [≤]14 days pre-surgery is well tolerated in adults awaiting cardiac surgery and is associated with upregulation of ferroptosis protection pathways and reductions in myocardial injury.
ER -